A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

National Taiwan University Hospital, Taipei

National Cheng Kung University Hospital, Tainan City

Inselspital Bern, Bern

Mount Sinai Medical Center, New York

National Cancer Center, Gyeonggi-do

IRCCS Foundation - National Institute of Tumors, Milan

University of Miami - Sylvester Comprehensive Cancer Center, Miami

H. Lee Moffitt Cancer Center, Tampa

Johannes Gutenberg University Mainz - University Medical Center, Mainz

University of Frankfurt, Frankfurt

Ochsner Cancer Institute, New Orleans

Huntsman Cancer Institute, Salt Lake City

Hospital Beaujon, Clichy

Inland Empire Liver Foundation, Rialto

Institut Gustave Roussy, Villejuif

Jilin Cancer Hospital, Changchun

Jilin University the First Affiliated Hospital, Changchun

Harbin Medical University Cancer Hospital, Harbin

National Cancer Centre, Singapore

Fudan University Zhongshan Hospital, Xuhui

Fudan University Shanghai Cancer Center, Shanghai

The Chinese People's Liberation Army 81 Hospital, Nanjing

Nantong Tumor Hospital, Nantong

Tianjin Medical University Cancer Institute & Hospital, Hepatobiliary Oncology Department, Tianjin

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Hunan Cancer Hospital, Radioactive Interventional Department, Changsha

Henan Cancer Hospital, Zhengzhou

Nanfang Hospital, Guangzhou

West China Hospital, Sichuan University, Chengdu

Massachusetts General Hospital, Boston

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

Seoul National University Hospital, Seoul

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Vall d'Hebron Institute of Oncology, Barcelona

University of Liverpool - Clatterbridge Cancer Centre, Bebington

Royal Free Hospital, London

Guy's Hospital, London

University College London, London